CompletedPhase 1

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

United States, Germany25 participantsStarted 2022-12-08

Plain-language summary

This is a multicenter, open-label, parallel-group study to evaluate INCB054707 in participants with varying levels of renal function or impairment.

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Recent myocardial infarction (within 6 months of check-in).
✕. New York Heart Association Class III or IV congestive heart failure.
✕. Unstable angina (within 6 months of check-in).
✕. Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker).
✕. Uncontrolled hypertension.

Pharmacokinetics Parameter: Cmax of INCBC054707

Timeframe: Days 1 - 5

Pharmacokinetics Parameter: AUC(0-t) of INCB054707

Timeframe: Days 1 - 5

Pharmacokinetics Parameter: AUC(0-∞) of INCB054707

Timeframe: Days 1 - 5

NCT IDNCT05624710

SponsorIncyte Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-06-30